For example, growth hormone releasing hormone analogs—such as tesamorelin—have previously been shown to lead to a selective reduction of VAT in patients with obesity or HIV-associated lipodystrophy76,77. Here, GHRH is linked to obesity due to melanocortin 4 receptor deficiency.